Amylin, Takeda call off obesity treatment
San Diego: Amylin Pharmaceuticals Inc. and Takeda Pharmaceutical Co. Ltd. said Thursday that they are discontinuing development of pramlintide/metreleptin, a combination therapy to treat obesity.
The companies said the decision was based on a commercial assessment. Amylin`s senior vice president of research, Christian Weyer, said that in the future, the hope is to develop a similar treatment with "less frequent dosing."
Neither company expects to revise their latest fiscal 2011 guidance because of the development stoppage.